3 minute read

Health2Sync And Novo Nordisk Collaboration For Better Diabetes Management

April 30, 2022

Health2sync is supporting Novo Nordisk in developing a custom diabetes app for people with type 1 and type 2 diabetes using integrated insulin pens.

Insulin Therapy is a form of Therapy or Medical treatment of taking insulin to keep your blood sugar level in a normal range as much as possible. Patients with type 1 as well as type 2 diabetes require this type of treatment and they need to keep their Insulin Dose logs while undergoing insulin therapy. With everything going digital, patients are also looking for similar options to make their lives easier. This is what healthcare organisations like Health2sync as well as Novo Nordisk are working for dedicatedly. So, let’s see what the collaboration of these 2 organisations has in store for diabetes patients as well as the whole healthcare system.

Health2sync and Novo Nordisk:

Health2sync

Health2Sync established in Taiwan in 2013 aims to build simple healthcare solutions that incorporate mobile, digital therapeutics, and cloud-based services to manage chronic diseases. Health2Sync’s blood glucose monitoring system has already been used in several developing countries where medical resources are scarce or inadequate. More than half the world’s diabetic population lives in Asia, but less than 30% of diabetics receive adequate treatment.

Novo Nordisk

Novo Nordisk a Danish Foundation is a global healthcare company that provides innovative medicines and systems for diabetes, obesity and other serious chronic diseases. They develop, manufacture, distribute and market both biopharmaceuticals and medical devices to curtail the prevalence of these diseases. The company employs more than 47,000 people in 80 offices around the world and markets our products in 168 countries. For almost 100 years, we have been translating the unmet medical needs of people living with a serious chronic diseases into innovative medicines and delivery systems, like our insulin pens. Their treatments today are benefiting millions of people living with diabetes, obesity and rare blood and endocrine diseases. From their labs to their factory floors, they are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.

The Partnership between Health2sync and Novo Nordisk:

Novo Nordisk has teamed up with Taiwanese company Health2Sync to promote the latter’s digital diabetes management app in Japan. The two companies started localization efforts for the SyncHealth app, known as Health2Sync outside of Japan, as well as its web platform for patient management and communication with healthcare providers in December.

A century after insulin, a hormone that allows the human body to use glucose, was discovered, Health2Sync reported that between 150 and 200 million people worldwide require insulin treatment, but one in every two patients with type 2 diabetes is not being treated. Health2Sync’s support programme enables the integration of smart insulin pens with the Health2Sync app to help patients receiving insulin therapy achieve optimal glucose control through education and communication. Manga and animation are used in the programme to help children and adolescents with type 1 diabetes receive treatment information more easily. For the time being, the service is only available to Japanese patients, with plans to expand to “other markets in the region,” according to Deng.

The Future:

In the future, Novo Nordisk plans to allow diabetes patients to wirelessly sync their insulin delivery devices with an app, including the Freestyle Libre glucose monitor, and to automatically record self-injected drug data. The company is working through nonexclusive partnerships with Glooko and Abbott Diabetes Care Inc. to ensure compatibility with other diabetes-focused hardware and software on the market.

Sanofi, a French pharmaceutical company, partnered with Health2Sync in December of last year to help them roll out an in-development insulin management solution. Titration algorithms developed by Health2Sync’s developers will enable effective coordination of healthcare providers and patients. At the same time, Health2Sync finished an app development project with Abbott Laboratories in Japan in November, integrating continuous glucose monitoring data from the Abbott FreeStyle LibreLink mobile app. Users can now view their CGM data, as well as diet, weight, blood pressure, and exercise data captured by Fitbit, in the updated app.

Conclusion:

The digital age has been an absolute game-changer for the medical devices industry. From smart diagnostic tools to smart insulin pens and several other medical devices, digitisation has helped doctors, as well as patients, win their battle against diabetes. It’s an important revelation for a condition that affects millions of people across the world.Health2Sync and Novo Nordisk welcome all developers worldwide to join them in their mission which is to make a difference in the lives of diabetics around the world.

References: